Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trial.

Autor: Hsu D; Moderna, Cambridge, MA, USA. Electronic address: denise.hsu@modernatx.com., Jayaraman A; Moderna, Cambridge, MA, USA., Pucci A; Moderna, Cambridge, MA, USA., Joshi R; Moderna, Cambridge, MA, USA., Mancini K; Moderna, Cambridge, MA, USA., Chen HL; Moderna, Cambridge, MA, USA., Koslovsky K; Moderna, Cambridge, MA, USA., Mao X; Moderna, Cambridge, MA, USA., Choi A; Moderna, Cambridge, MA, USA., Henry C; Moderna, Cambridge, MA, USA., Vakil J; Moderna, Cambridge, MA, USA., Stadlbauer D; Moderna, Cambridge, MA, USA., Jorquera P; Moderna, Cambridge, MA, USA., Arunkumar GA; Moderna, Cambridge, MA, USA., Sanchez-Crespo NE; Research Center of America, Hollywood, FL, USA., Wadsworth LT; Sundance Clinical Research, St Louis, MO, USA., Bhupathy V; Long Beach Research Institute, Long Beach, CA, USA., Du E; Moderna, Cambridge, MA, USA., Avanesov A; Moderna, Cambridge, MA, USA., Ananworanich J; Moderna, Cambridge, MA, USA., Nachbagauer R; Moderna, Cambridge, MA, USA.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Sep 05. Date of Electronic Publication: 2024 Sep 05.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Chapter 11. Sc, Y, the lanthanides and the actinides.

Autor: Lyle, S. J.

Publikováno v: Annual Reports on the Progress of Chemistry: Section A; 1981, Vol. 78, p299-312, 14p